- Home
- RZLV vs OLMA Comparison
RZLV vs OLMA Comparison
Compare RZLV & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RZLV
- OLMA
- Stock Information
- Founded
- RZLV 2016
- OLMA 2006
- Country
- RZLV United Kingdom
- OLMA United States
- Employees
- RZLV N/A
- OLMA N/A
- Industry
- RZLV
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- RZLV
- OLMA Health Care
- Exchange
- RZLV NYSE
- OLMA Nasdaq
- Market Cap
- RZLV 474.9M
- OLMA 383.1M
- IPO Year
- RZLV N/A
- OLMA 2020
- Fundamental
- Price
- RZLV $2.55
- OLMA $4.99
- Analyst Decision
- RZLV Strong Buy
- OLMA Strong Buy
- Analyst Count
- RZLV 4
- OLMA 4
- Target Price
- RZLV $5.50
- OLMA $28.33
- AVG Volume (30 Days)
- RZLV 6.1M
- OLMA 1.0M
- Earning Date
- RZLV 02-21-2025
- OLMA 03-10-2025
- Dividend Yield
- RZLV N/A
- OLMA N/A
- EPS Growth
- RZLV N/A
- OLMA N/A
- EPS
- RZLV N/A
- OLMA N/A
- Revenue
- RZLV $151,686.00
- OLMA N/A
- Revenue This Year
- RZLV $103.93
- OLMA N/A
- Revenue Next Year
- RZLV $11,308.05
- OLMA N/A
- P/E Ratio
- RZLV N/A
- OLMA N/A
- Revenue Growth
- RZLV 25.96
- OLMA N/A
- 52 Week Low
- RZLV $1.57
- OLMA $4.60
- 52 Week High
- RZLV $14.50
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- RZLV N/A
- OLMA 38.98
- Support Level
- RZLV N/A
- OLMA $4.94
- Resistance Level
- RZLV N/A
- OLMA $5.34
- Average True Range (ATR)
- RZLV 0.00
- OLMA 0.42
- MACD
- RZLV 0.00
- OLMA -0.03
- Stochastic Oscillator
- RZLV 0.00
- OLMA 11.39
About RZLV REZOLVE AI LTD
Rezolve AI Ltd provides a mobile commerce and engagement platform, underpinned by machine learning, that enables retailers, brands and manufacturers to engage with consumers in a broad range of locations and settings via their mobile devices and personal computers. its platform allows for mobile engagement with merchants using its software to extend their business to consumers' mobile devices and computers in different ways.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.